Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model

Seasonal influenza vaccination takes into account primarily hemagglutinin (HA)-specific neutralizing antibody responses. However, the accumulation of substitutions in the antigenic regions of HA (i.e., antigenic drift) occasionally results in a mismatch between the vaccine and circulating strains. To prevent poor vaccine performance, we investigated whether an antigenically matched neuraminidase (NA) may compensate for reduced vaccine efficacy due to a mismatched HA. Ferrets were vaccinated twice with adjuvanted split inactivated influenza vaccines containing homologous HA and NA (vacH3N2), only homologous HA (vacH3N1), only homologous NA (vacH1N2), heterologous HA and NA (vacH1N1), or phosphate-buffered saline (vacPBS), followed by challenge with H3N2 virus (A/Netherlands/16190/1968). Ferrets vaccinated with homologous HA (vacH3N2 and vacH3N1) displayed minimum fever and weight loss compared to vacH1N1 and vacPBS ferrets, while ferrets vaccinated with NA-matched vacH1N2 displayed intermediate fever and weight loss. Vaccination with vacH1N2 further led to a reduction in virus shedding from the nose and undetectable virus titers in the lower respiratory tract, similarly to when the homologous vacH3N2 was used. Some protection was observed upon vacH1N1 vaccination, but this was not comparable to that observed for vacH1N2, again highlighting the important role of NA in vaccine-induced protection. These results illustrate that NA antibodies can prevent severe disease caused by influenza virus infection and that an antigenically matched NA in seasonal vaccines might prevent lower respiratory tract complications. This underlines the importance of considering NA during the yearly vaccine strain selection process, which may be particularly beneficial in seasons when the HA component of the vaccine is mismatched. IMPORTANCE Despite the availability of vaccines, influenza virus infections continue to cause substantial morbidity and mortality in humans. Currently available influenza vaccines take primarily the hemagglutinin (HA) into account, but the highly variable nature of this protein as a result of antigenic drift has led to a recurrent decline in vaccine effectiveness. While the protective effect of neuraminidase (NA) antibodies has been highlighted by several studies, there are no requirements with regard to quantity or quality of NA in licensed vaccines, and NA immunity remains largely unexploited. Since antigenic changes in HA and NA are thought to occur asynchronously, NA immunity could compensate for reduced vaccine efficacy when drift in HA occurs. By matching and mismatching the HA and NA components of monovalent split inactivated vaccines, we demonstrated the potential of NA immunity to protect against disease, virus replication in the lower respiratory tract, and virus shedding in the ferret model.

Medienart:	E-Artikel

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	Zur Gesamtaufnahme - volume:96
Enthalten in:	Journal of virology - 96(2022), 6 vom: 23. März, Seite e0195921

Sprache:	Englisch

Beteiligte Personen:	Rosu, Miruna E [VerfasserIn] Kok, Adinda [VerfasserIn] Bestebroer, Theo M [VerfasserIn] de Meulder, Dennis [VerfasserIn] Verveer, Elwin P [VerfasserIn] Pronk, Mark R [VerfasserIn] Dekker, Lennard J M [VerfasserIn] Luider, Theo M [VerfasserIn] Richard, Mathilde [VerfasserIn] van den Brand, Judith M A [VerfasserIn] Fouchier, Ron A M [VerfasserIn] Herfst, Sander [VerfasserIn]

Links:	Volltext

Themen:	Antibodies, Viral EC 3.2.1.18 Ferret Hemagglutinins Inactivated vaccines Influenza Vaccines Influenza virus Journal Article NI antibodies Neuraminidase Research Support, N.I.H., Extramural Vaccines, Inactivated

Anmerkungen:	Date Completed 28.04.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE

doi:	10.1128/jvi.01959-21

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM336409494